BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-423@pharmaconomics
DTSTAMP:20260707T015842Z
DTSTART;VALUE=DATE:20260109
DTEND;VALUE=DATE:20260110
SUMMARY:ATRA CRL — tabelecleucel
DESCRIPTION:An FDA complete response letter on tabelecleucel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) is in focus around Jan 9\, 2026.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1604464/000119312526219420/atra-ex99_1.htm\n\nTrack it: https://pharmaconomics.com/e/423
URL:https://pharmaconomics.com/e/423
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ATRA catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR